| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 山竹醇与环糊精络合物及其方法 | CN201180067149.6 | 2011-01-25 | CN103459362B | 2015-11-25 | 苏尼尔·巴斯卡兰; 莫汉·威斯瓦拉曼 |
| 本发明公开了山竹醇与环糊精化学络合的药物分子，以及该络合分子在预防和管理心功能不全中的用途，所述心功能不全由化疗、药物和/或其他因生活方式及疾病所致的心脏损害引起。本发明还涉及从藤黄物种中提取和提纯高产量的95-99%纯度的山竹醇的方法，以及使山竹醇与环糊精化学络合、以提高其稳定度和生物利用率的方法。 | ||||||
| 2 | 双[硫代酰肼酰胺]化合物的过渡金属络合物 | CN200980151296.4 | 2009-10-21 | CN102256949A | 2011-11-23 | 永井雅纯; 沈建华 |
| 本发明涉及一种化合物，该化合物包含与过渡金属阳离子络合的双[硫代酰肼酰胺]或其去质子化形式，其中，所述双[硫代酰肼酰胺]由结构式(I)表示：或其前药、异构体、酯、盐、水合物、溶剂化物、多晶型或去质子化形式。本发明还提供一种包含本发明的化合物的药物组合物和其使用方法。 | ||||||
| 3 | 双[硫代酰肼酰胺]化合物的过渡金属络合物 | CN200980151296.4 | 2009-10-21 | CN102256949B | 2014-09-24 | 永井雅纯; 沈建华 |
| 本发明涉及一种化合物，该化合物包含与过渡金属阳离子络合的双[硫代酰肼酰胺]或其去质子化形式，其中，所述双[硫代酰肼酰胺]由结构式(I)表示：或其前药、异构体、酯、盐、水合物、溶剂化物、多晶型或去质子化形式。本发明还提供一种包含本发明的化合物的药物组合物和其使用方法。 | ||||||
| 4 | 山竹醇与环糊精络合物及其方法 | CN201180067149.6 | 2011-01-25 | CN103459362A | 2013-12-18 | 苏尼尔·巴斯卡兰; 莫汉·威斯瓦拉曼 |
| 本发明公开了山竹醇与环糊精化学络合的药物分子，以及该络合分子在预防和管理心功能不全中的用途，所述心功能不全由化疗、药物和/或其他因生活方式及疾病所致的心脏损害引起。本发明还涉及从藤黄物种中提取和提纯高产量的95-99%纯度的山竹醇的方法，以及使山竹醇与环糊精化学络合、以提高其稳定度和生物利用率的方法。 | ||||||
| 5 | Method for separation of racemic compound-forming chiral substances by a cyclic crystallization process and a crystallization device | US13368638 | 2012-02-08 | US20120197040A1 | 2012-08-02 | Heike LORENZ; Daniel POLENSKE; Linzhu KLUKAS; Andreas SEIDEL-MORGENSTERN |
| The invention concerns a method for separating a racemic compound-forming chiral substance by a cyclic crystallization process which is conducted in at least one first crystallization unit (10) and in at least one second crystallization unit (18), wherein in a first process cycle an enantiomer is crystallized in the first crystallization unit (10) and a racemic compound is crystallized in the second crystallization unit (18), wherein in a second process cycle the enantiomer is crystallized in the second crystallization unit (18) and the racemic compound is crystallized in the first crystallization unit (10), wherein during each process cycle in at least one process sub-step (B→C, F→G) a mother liquor (12) being contained in the first crystallization unit (10) is mutually exchanged with a mother liquor (20) being contained in the second crystallization unit (18). An auto-seeding process sub-step is applied at the beginning of a process cycle. | ||||||
| 6 | Combinatorial Electrochemical Synthesis | US09746840 | 2000-12-22 | US20020008038A1 | 2002-01-24 | Adam Heller; Daren J. Caruana |
| Abstract of DisclosureAn array of selectively addressible microelectrodes for combinatorial synthesis of complex polymers or alloys. | ||||||
| 7 | Method for separating racemic compounds formed chiral substance by a circulation crystallization process and crystallization devices | JP2012527298 | 2010-08-31 | JP2013503832A | 2013-02-04 | ローレンツ、ハイケ; ポランスキ、ダニエル; クルカス、リンツ; セイデル‐モルゲン‐シュターン、アンドレアス |
| The invention concerns a method for separating a racemic compound-forming chiral substance by a cyclic crystallization process which is conducted in at least one first crystallization unit (10) and in at least one second crystallization unit (18), wherein in a first process cycle an enantiomer is crystallized in the first crystallization unit (10) and a racemic compound is crystallized in the second crystallization unit (18), wherein in a second process cycle the enantiomer is crystallized in the second crystallization unit (18) and the racemic compound is crystallized in the first crystallization unit (10), wherein during each process cycle in at least one process sub-step (B†’C, F†’G) a mother liquor (12) being contained in the first crystallization unit (10) is mutually exchanged with a mother liquor (20) being contained in the second crystallization unit (18). An auto-seeding process sub-step is applied at the beginning of a process cycle. | ||||||
| 8 | TRANSITION METAL COMPLEXES OF A BIS[THIOHYDRAZIDE AMIDE] COMPOUND | US14455458 | 2014-08-08 | US20150031758A1 | 2015-01-29 | Masazumi Nagai; Jianhua Shen |
| The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thiohydrazide amide] is represented by Structural Formula (I): or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. The present invention also provides a pharmaceutical composition comprising a compound of the invention and method of use thereof. | ||||||
| 9 | TRANSITION METAL COMPLEXES OF A BIS[THIOHYDRAZIDE AMIDE] COMPOUND | US13902270 | 2013-05-24 | US20140011864A1 | 2014-01-09 | Masazumi Nagai; Jianhua Shen |
| The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thiohydrazide amide] is represented by Structural Formula (I): or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. The present invention also provides a pharmaceutical composition comprising a compound of the invention and method of use thereof. | ||||||
| 10 | Transition metal complexes of a bis[thio-hydrazide amide] compound | US13125016 | 2009-10-21 | US08461199B2 | 2013-06-11 | Nagai Masazumi; Jianhua Shen |
| The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thiohydrazide amide] is represented by Structural Formula (I): or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. The present invention also provides a pharmaceutical composition comprising a compound of the invention and method of use thereof. | ||||||
| 11 | COMPLEX OF GARCINOL, CYCLODEXTRIN AND METHOD THEREOF | US13016541 | 2011-01-28 | US20120148504A1 | 2012-06-14 | Sunil Bhaskaran; Mohan Vishwaraman |
| The present disclosure discloses a pharmaceutical molecule of Garcinol chemically complexed with cyclodextrins and the use of the complexed molecule in prevention and management of cardiac dysfunction induced by chemotherapy, drugs and/or other insults to the heart caused by lifestyle and disease conditions. The disclosure also relates to a method of extraction and purification of high yield of 95-99% pure Garcinol from Garcinia species and a method of chemically complexing Garcinol with cyclodextrins to improve its stability and bioavailability. | ||||||
| 12 | Nanoparticle structures utilizing synthetic DNA lattices | US09733968 | 2000-12-12 | US20020022111A1 | 2002-02-21 | Charles T. Black; Stephen M. Gates; Christopher B. Murray; Shouheng Sun |
| A laminar structure upon a substrate is formed from a) a lattice layer comprising DNA (deoxyribonucleic acid) segments arranged to form cells of the lattice layer, and b), at least one nanoparticle being disposed within each cell of the lattice layer. The nanoparticles are preferably of substantially uniform diameter not exceeding 50 nanometers. A coating may be applied to adhere the the particles to the substrate and to maintain their substantially uniform spaced-apart relationship. The DNA lattice layer is fabricated using known automated synthetis methods, and is designed to contain specific nucleotide base sequences which cause the DNA to form an ordered array of openings, or lattice cells, by self-assembly. Self-assembly of the DNA lattice may be at an air-liquid interface, or in solution. A preferred embodiment is a magnetic storage medium in which the particles are magnetic particles with diameters in the range of 5-20 nm., the particles being organized in square information bits with each bit holding of 4, 9, 16, 25 etc. particles to produce areal information storage densities on the order of 1000 gigabits (one terabit) per square inch. The lattice of bits may be stabilized and protected by a deposited thin film, hard, abrasion-resistant coating. | ||||||
| 13 | TRANSITION METAL COMPLEXES OF A BISÝTHIOHYDRAZIDE AMIDE¨COMPOUND | EP09822631.9 | 2009-10-21 | EP2373624A1 | 2011-10-12 | NAGAI, Masazumi; SHEN, Jianhua |
| The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thiohydrazide amide] is represented by Structural Formula (I): or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. The present invention also provides a pharmaceutical composition comprising a compound of the invention and method of use thereof. | ||||||
| 14 | Method for separation of racemic compound-forming chiral substances by a cyclic crystallization process and a crystallization device | EP09169202.0 | 2009-09-02 | EP2292306B1 | 2013-05-01 | Lorenz, Heike, Dr.; Polenske, Daniel, Dipl.-Ing.; Klukas, Linzhu, Dipl.-Ing.; Seidel-Morgenstern, Andreas, Prof. Dr.-Ing. |
| The invention concerns a method for separating a racemic compound-forming chiral substance by a cyclic crystallization process which is conducted in at least one first crystallization unit (10) and in at least one second crystallization unit (18), wherein in a first process cycle an enantiomer is crystallized in the first crystallization unit (10) and a racemic compound is crystallized in the second crystallization unit (18), wherein in a second process cycle the enantiomer is crystallized in the second crystallization unit (18) and the racemic compound is crystallized in the first crystallization unit (10), wherein during each process cycle in at least one process sub-step (B†’C, F†’G) a mother liquor (12) being contained in the first crystallization unit (10) is mutually exchanged with a mother liquor (20) being contained in the second crystallization unit (18). An auto-seeding process sub-step is applied at the beginning of a process cycle. | ||||||
| 15 | Liquid crystalline compounds and process for producing the same | EP98102929.1 | 1998-02-19 | EP0860417A2 | 1998-08-26 | Hanna, Junichi, c/o Dai Nippon Printing Co., Ltd.; Funahashi, Masahiro, Dai Nippon Printing Co., Ltd.; Kafuku, Komei; Kogo, Kyoko, c/o Dai Nippon Printing Co., Ltd. |
A liquid crystalline compound having a novel structure and a process for producing the same are provided. The liquid crystalline compound is represented by the following general formula (I):
|
||||||
| 16 | Garcinol, complex and method of the cyclodextrin | JP2013542629 | 2011-01-25 | JP2014503514A | 2014-02-13 | スニル・バースカラン; モハン・ヴィシュワラマン |
| 本開示は、シクロデキストリンと化学複合体を形成したガルシノールの医薬分子、ならびに化学療法、薬物、および/または生活様式や疾患状態により引き起こされる心臓への他の損傷によって誘発される心臓機能障害の予防および管理における前記複合体分子の使用を開示する。 本開示はまた、ガルシニア属種から純度95〜99%のガルシノールを高収率で抽出および精製する方法、ならびにガルシノールの安定性および生体利用率を改善するために、ガルシノールをシクロデキストリンと化学複合体を形成させる方法にも関する。 | ||||||
| 17 | Electroluminescence element composition | JP4959397 | 1997-02-19 | JP4116109B2 | 2008-07-09 | 公明 加福; 純一 半那; 恭子 古後; 正浩 舟橋 |
| 18 | Liquid crystal compound and its production | JP4959397 | 1997-02-19 | JPH10231260A | 1998-09-02 | HANNA JUNICHI; FUNAHASHI MASAHIRO; KAFUKU MASAAKI; KOGO KYOKO |
| PROBLEM TO BE SOLVED: To produce a new liquid crystal compound showing liquid crsytrallinity and also charge transporting properties and useful as a mateial for an optical sensor, a photoconductor, etc. SOLUTION: This liquid crystal compound is a compound of formula I (R 1 and R 2 are each a 1-22C hydrocarbon group; R 3 is H, cyano, etc.; X 1 and X 2 are each O, S, CO, etc.), e.g. compound of formula II. The compound of formula I is obtained by reacting a compound of formula III with a compound of formula IV. COPYRIGHT: (C)1998,JPO | ||||||
| 19 | Complex of garcinol, cyclodextrin and method thereof | US14593882 | 2015-01-09 | US09956301B2 | 2018-05-01 | Sunil Bhaskaran; Mohan Vishwaraman |
| The present disclosure discloses a pharmaceutical molecule of Garcinol chemically complexed with cyclodextrins and the use of the complexed molecule in prevention and management of cardiac dysfunction induced by chemotherapy, drugs and/or other insults to the heart caused by lifestyle and disease conditions. The disclosure also relates to a method of extraction and purification of high yield of 95-99% pure Garcinol from Garcinia species and a method of chemically complexing Garcinol with cyclodextrins to improve its stability and bioavailability. | ||||||
| 20 | COMPLEX OF GARCINOL, CYCLODEXTRIN AND METHOD THEREOF | US14593882 | 2015-01-09 | US20150196669A1 | 2015-07-16 | Sunil Bhaskaran; Mohan Vishwaraman |
| The present disclosure discloses a pharmaceutical molecule of Garcinol chemically complexed with cyclodextrins and the use of the complexed molecule in prevention and management of cardiac dysfunction induced by chemotherapy, drugs and/or other insults to the heart caused by lifestyle and disease conditions. The disclosure also relates to a method of extraction and purification of high yield of 95-99% pure Garcinol from Garcinia species and a method of chemically complexing Garcinol with cyclodextrins to improve its stability and bioavailability. | ||||||
QQ群二维码
意见反馈
意见反馈